Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms AESOP
- Sponsors Intercept Pharmaceuticals
- 09 Mar 2020 Results investigating the efficacy and safety of Obeticholic-acid in patients with Primary-sclerosing-cholangitis, published in the Journal of Hepatology
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 23 Oct 2017 Results presented in an Intercept Pharmaceuticals media release.